SynthesisEuropean heart journal2016
Implantable cardioverter-defibrillators in adults with congenital heart disease: a systematic review and meta-analysis.
Synthesis in European heart journal, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 38 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
38 citing papers in PubMed, 2 syntheses or guidelines pooled it, 116 citations in OpenAlex.
- Investigating the Cost-Effectiveness of Telemonitoring Patients With Cardiac Implantable Electronic Devices: Systematic Review.Journal of medical Internet research · 2024Pooled it
- Predictors of Late Mortality in D-Transposition of the Great Arteries After Atrial Switch Repair: Systematic Review and Meta-Analysis.Journal of the American Heart Association · 2019Pooled it
- Predictors of Appropriate Implantable Cardioverter-Defibrillator Intervention in Adults with Congenital Heart Disease.Journal of clinical medicine · 2026Article
- Wearable Cardioverter-Defibrillator in Adult Congenital Heart Disease: A Bridge to Decision, Recovery, and Advanced Therapies.Heart failure reviews · 2026Review
- Strategies for preventing arrhythmic sudden death in adult congenital heart disease.European heart journal supplements : journal of the European Society of Cardiology · 2026Article
- Implantable Cardioverter-Defibrillator Therapy in Patients With Transposition of the Great Arteries: A Systematic Review of the Literature.CJC pediatric and congenital heart disease · 2025Review
- Combined subcutaneous implantable cardioverter defibrillator and pacemaker devices in complex congenital heart disease: a single-center experienced based study.Journal of interventional cardiac electrophysiology : an international journal of arrhythmias and pacing · 2025Article
- Diagnosis, management, and outcome of heart failure in congenitally corrected transposition of the great arteries (ccTGA)-a narrative review.Cardiovascular diagnosis and therapy · 2025Review
- Long-term outcomes of ventricular tachycardia ablation in repaired tetralogy of Fallot: Systematic review and meta-analysis.Journal of arrhythmia · 2024Article
- Trends in cardiac implantable electronic device utilization in adults with congenital heart disease: a US nationwide analysis.Journal of interventional cardiac electrophysiology : an international journal of arrhythmias and pacing · 2024Article
- Outcomes of permanent pacemakers and implantable cardioverter-defibrillators in an adult congenital heart disease population.International journal of cardiology. Congenital heart disease · 2024Article
- Arrhythmic Risk in Shone Complex: Lumping the Heterogeneity Together.JACC. Advances · 2024Article
- Arrhythmias in Patients with Congenital Heart Disease: An Ongoing Morbidity.Journal of clinical medicine · 2023Review
- Evolution of Pacemakers and Implantable Cardioverter Defibrillators (ICDs) in Cardiology.Cureus · 2023Review
- Brazilian Guidelines for Cardiac Implantable Electronic Devices - 2023.Arquivos brasileiros de cardiologia · 2023Article
- Peak Oxygen Uptake on Cardiopulmonary Exercise Test Is a Predictor for Severe Arrhythmic Events during Three-Year Follow-Up in Patients with Complex Congenital Heart Disease.Journal of cardiovascular development and disease · 2022Article
- The validity of current implantable cardioverter-defibrillator guidelines in a real-world population of adults with congenital heart disease: A single-center experience.International journal of cardiology. Congenital heart disease · 2022Article
- Implantable loop recorder for monitoring patients with congenital heart disease.Cardiovascular diagnosis and therapy · 2021Article
- Eligibility for subcutaneous implantable cardioverter-defibrillator in adults with congenital heart disease.ESC heart failure · 2021Article
- Narrative review of: risk stratification and implantable cardioverter-defibrillator therapy in adults with congenital heart disease.Cardiovascular diagnosis and therapy · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
aimsSudden cardiac death is a major cause of mortality in adult congenital heart disease (ACHD) patients. The indications for implantable cardioverter-defibrillator (ICD) implantation in ACHD patients are still not well established. We aim to systematically review the literature on indications and outcome of ICD implantation in ACHD patients. METHODS AND
resultsWe performed a comprehensive search in EMBASE, MEDLINE, and Google Scholar to identify all studies on ICD implantation in ACHD patients. We used random effects models to calculate proportions and 95% confidence intervals. Of 1356 articles, 24 studies with 2162 patients were included, with a mean follow-up of 3.6 ± 0.9 years. Half of patients had tetralogy of Fallot. Mean age at implantation was 36.5 ± 5.5 years old and 66% was male. Implantable cardioverter-defibrillators were implanted for primary prevention in 53% (43.5-62.7). Overall, 24% (18.6-31.3) of patients received one or more appropriate ICD interventions (anti-tachycardia pacing or shocks) during 3.7 ± 0.9 years: 22% (16.9-28.8) of patients with primary prevention in 3.3 ± 0.3 years and 35% (26.6-45.2) of patients with secondary prevention in 4.3 ± 1.2 years. Inappropriate shocks occurred in 25% (20.1-31.0) in 3.7 ± 0.8 years and other, particularly lead-related complications in 26% (18.9-33.6) of patients in 3.8 ± 0.8 years. All-cause mortality was 10% during 3.7 ± 0.9 years.
conclusionsIn ACHD, remarkably high rates of appropriate ICD therapy were reported, both in primary and secondary prevention. Because of the young age and lower death rates, the cumulative beneficial effects are likely greater in ACHD patients than in acquired heart disease patients. However, considering the high rates of inappropriate shocks and complications, case-by-case weighing of costs and benefits, remains essential.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.